Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant

• Published in: Leukemia Vol. 35; no. 6; pp. 1563 - 1570
• Main Authors: Zhang, Cheng, Wang, Xiao-Qi, Zhang, Rong-Li, Liu, Fang, Wang, Yi, Yan, Zhi-Ling, Song, Yong-Ping, Yang, Ting, Li, Ping, Wang, Zhen, Ma, Ying-Ying, Gao, Lei, Liu, Yao, Gao, Li, Kong, Pei-Yan, Liu, Jun, Tan, Xu, Zhong, Jiang F., Chen, Yu-Qing, Liang, Ai-Bin, Ren, Jin-Hua, Li, Zhen-Yu, Cao, Jiang, Gao, Quan-Li, Zhou, Jian, Gao, Ying, Zhang, Ding, Fan, Fang-Yi, Han, Ming-Zhe, Gale, Robert Peter, Zhang, Xi
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.06.2021; Nature Publishing Group
• Subjects: 38/77; 45/100; 631/67/1059/2325; 692/699/1541/1990/283/2125; Acute lymphoblastic leukemia; Acute lymphocytic leukemia; Antigen receptors, T cell; Antigens; Cancer; Cancer Research; Care and treatment; CD19 antigen; Cell therapy; Cellular therapy; Chimeric antigen receptors; Confidence intervals; Critical Care Medicine; Cytokines; Development and progression; Graft-versus-host reaction; Health aspects; Hematology; Intensive; Internal Medicine; Leukemia; Lymphatic leukemia; Lymphocytes; Lymphocytes B; Lymphocytes T; Medicine; Medicine & Public Health; Methods; Neurotoxicity; Oncology; Oncology, Experimental; Patient outcomes; Receptors; Remission; Survival; T cells; China

Safety and efficacy of allogeneic anti-CD19 chimeric antigen receptor T cells (CAR-T cells) in persons with CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) relapsing after an allotransplant remain unclear. Forty-three subjects with B-ALL relapsing post allotransplant received CAR-T cells w...